The head of the Research and Industrial Affairs Department of the General Staff of Iran Armed Forces admitted on Radio Goftogoo that there's sabotage and delay in issuing license to produce the Iranian vaccine of Fakhra;"This vaccine has...
The head of the Research and Industrial Affairs Department of the General Staff of Iran Armed Forces admitted on Radio Goftogoo that there's sabotage and delay in issuing license to produce the Iranian vaccine of Fakhra; "This vaccine has a very strong immunogenicity with no side effects."
According to Radio Goftogoo news site, Commander Dr. Mohammad Azizi Delshad, head of the Research and Industrial Affairs Department of the General Staff of Iran Armed Forces, had a phone call interview with "Morning Dialogue" program about the center's management views on the production of Iranian vaccine of Fakhra.
Sardar Azizi stated that the power to deal with biological threats is one of the most important issues in the armed forces of all countries in order to maintain security; "Such intelligence also exist in the Islamic Republic of Iran."
"As soon as Covid-19 crisis broke out, the Armed Forces provided assistance besides making lots of efforts and successes in the scientific field. Even the first Covid-19 diagnostic kit was an achievement of our Armed Forces at the Department of Defense," he added.
The Head of Research and Industrial Affairs of the General Staff of Iran Armed Forces mentioned that production of this vaccine was a strategic step against Covid-19; "All the assistance, efforts, and measures taken so far was for managing this crisis, but the vaccine is a fundamental and principled solution."
Sardar Azizi reminded; "The Defense Research and Innovation Organization in the Armed Forces, began to work on vaccine production under the supervision of Martyr Fakhrizadeh. Another achievement was reached at Baqiyatallah University of the IRGC, and we will hear good news about their vaccines in near future."
He spoke about the success of the experimental stages of the killed vaccine of Fakhra; "in the first phase of the clinical trial, the vaccine was injected into 135 people and it was found that this vaccine has a very strong immunogenicity. At the same time we can say that it has no side effects."
The head of the Research and Industrial Affairs Department of the General Staff of Iran Armed Forces acknowledged that there was sabotage and delay in issuing license for production of the Iranian vaccine of Fakhra; "Fakhra vaccine went through a completely scientific path and was not given any emergency licenses. Fakhra vaccine could have helped in solving the society's problems much earlier, but it will soon become widely available in the next few months."
Commander Azizi noted; "We hope that in the second phase, an emergency permit will be issued for the use of this vaccine resulting in the vaccination of our people at the same time."
By Mojgan Mahdavi
